Browse > Home / Actoplus / Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting

October 24, 2009

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical party, today announced that positive data from two investigator-initiated studies through ZEGERID® (omeprazole/sodium bicarbonate) have being inclined exist presented in poster sessions at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting seizure courtyard in San Diego. These studies were supported by grants from Santarus.

Poster P424: Randomized Open-Label Trial to Assess the Impact of Dosage Timing of Omeprazole/Sodium Bicarbonate (Zegerid 40 mg) on Healing of Severe Reflux Esophagitis: Preliminary Results
(D Francis, MD, et al) - Monday, October 26, 2009, 10:30 a.m. – 4:00 p.fray. Pacific Time

This poster discusses preliminary results from a prospective open-label con over with ZEGERID 40 mg administered in spite of 8 weeks, either in the morning previous to breakfast or at bedtime, in treating subjects with severe erosive esophagitis (LA Grade C and D). For optimal efficacy, proton pump inhibitors (PPIs) are taken on an empty stomach 20 to 60 minutes previous to a meal, which can be cumbersome. The purpose of the study is to determine on the supposition that ZEGERID taken at bedtime offers an choice option for the treatment of severe erosive esophagitis. The end is to banquet 100 subjects>

Poster P833: Retrospective Assessment of Immediate-Release Omeprazole/Sodium Bicarbonate in Improvement of GERD Symptoms in Patients Who Failed Delayed-Release Proton Pump Inhibitors
(J Jolley, MD) - Tuesday, October 27, 2009, 10:30 a.m. – 4:00 p.m. Pacific Time

This open-label retroactive review of medicinal records from 50 patients who failed one or more delayed-release proton pump inhibitors (PPIs) evaluated the effectiveness of ZEGERID 40 mg in controlling symptoms of gastroesophageal ebb. disease (GERD).

Source: Santarus, Inc.

Written by Samanta · Filed Under Actoplus